Recommendation of the President – Spevigo (spesolimab)
On 6 February 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 18/2026 on the reimbursement of the medicinal product Spevigo (spesolimab) under the drug program “Treatment of patients with psoriasis (ICD-10: L40.0, L40.1)” for the indication: treatment of exacerbations of generalized pustular psoriasis (GPP)